Article Contents ::
- 1 The Brand Name BEEMINE Has Generic Salt :: Neostigmine
- 2 BEEMINE Is From Company BIOMIICRON Priced :: Rs. 21.2
- 3 BEEMINE have Neostigmine is comes under Sub class Drugs for Neurodegenerative Disorders of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Drugs for Neurodegenerative Disorders
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name BEEMINE Has Generic Salt :: Neostigmine
BEEMINE Is From Company BIOMIICRON Priced :: Rs. 21.2
BEEMINE have Neostigmine is comes under Sub class Drugs for Neurodegenerative Disorders of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Drugs for Neurodegenerative Disorders
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 5ML|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From BIOMIICRON :: BEEMINE||Neostigmine||Nervous System||Drugs for Neurodegenerative Disorders|
Indications for Drugs ::
Myasthenia gravis, Paralytic ileus; Post-op urinary retention, Reversal of nondepolarising neuromuscular blockade
Drug Dose ::
Adult: IV Reversal of non depolarising neuromuscular blockade As metilsulfate: 50-70 mcg/kg via inj. Child: As metilsulfate: Children: 0.025-0.08 mg/kg/dose. Infants: 0.025-0.1 mg/kg/dose. IM Diagnosis of myasthenia gravis As metilsulfate: 0.02 mg/kg as a single dose. Discontinue all anticholinesterase medications for at least 8 hr prior to administration. IM/SC Myasthenia gravis As metilsulfate: 0.5-2.5 mg at intervals, up to a total dose of 5-20 mg/day. Paralytic ileus; Post-op urinary retention As metilsulfate: 0.5 mg. Renal impairment: CrCl (ml/min) 10-50 50% of normal dose. <10 25% of normal dose. Contraindication ::
Mechanical GI or urinary tract obstruction, peritonitis.
Drug Precautions ::
Patients with epilepsy, bronchial asthma, bradycardia, recent MI, hypotension, vagotonia, hyperthyroidism, recent intestinal or bladder surgery, renal impairment, arrhythmias, peptic ulcer. Distinguish cholinergic crisis due to overdosage from myasthenic crisis. Pregnancy and lactation. Atropine should always be available when given by inj.
Drug Side Effects ::
Increased salivation and sweating, nausea and vomiting, abdominal cramps, diarrhoea, allergic reactions, rash (bromide salt), miosis, increased bronchial secretions, bradycardia, bronchospasm, weakness, muscle cramps, fasciculation, hypotension. Potentially Fatal: Anaphylaxis.
Pregnancy category ::
Drug Mode of Action ::
Neostigmine reversibly inhibits acetylcholinesterase and thus potentiates the nicotinic and muscarinic effects of acetylcholine. This facilitates the transmission of impulses across myoneural junction.
Drug Interactions ::
May reduce effects of anticholinergics. May increase effects of cholinergic agonists. Increased risk of bradycardia with digoxin, diltiazem, verapamil or beta-blockers without intrinsic sympathomimetic activity. Increased muscle weakness and decreased response to anticholinesterases with corticosteroids. May increase effects of depolarising neuromuscular blockers. Effects may be antagonised by drugs with neuromuscular blocking activity e.g. aminoglycosides, clindamycin, colistin, cyclopropane, halogenated inhalational anaesthetics. Effects may be reduced by quinine, chloroquine, hydroxychloroquine, quinidine, procainamide, propafenone, lithium, ?-blockers. Possible additive toxicity with ophthalmic use of anticholinesterases e.g. ecothiopate.